reduce coronavirus infection by 70% in lab studies, with researchers calling for additional clinical trials among hospitalized COVID-19 patients.A team of researchers from the U.K.
and Italy published findings in the Frontiers in Pharmacology journal Friday, finding that fenofibrate and fenofibric acid resulted in a significant reduction in coronavirus infection in human cells when the drug was used in safe and approved concentrations, according to a news release posted Friday.RELATED: Expert says US dealing with COVID-19 variant 'with more tricks in its bag'"Our data indicates that fenofibrate may have the potential to reduce the severity of COVID-19 symptoms and also virus spread," Dr.